Market Capitalization (Millions $) |
759 |
Shares
Outstanding (Millions) |
63 |
Employees |
- |
Revenues (TTM) (Millions $) |
8 |
Net Income (TTM) (Millions $) |
-193 |
Cash Flow (TTM) (Millions $) |
-199 |
Capital Exp. (TTM) (Millions $) |
12 |
Verve Therapeutics Inc
Verve Therapeutics Inc. is a biotechnology company founded in 2019, with headquarters in Cambridge, Massachusetts. The company is dedicated to developing gene-editing therapies for cardiovascular diseases.
Verve Therapeutics uses the latest advancements in the field of genetic engineering, like CRISPR/Cas9, to create therapeutics that will eliminate the genetic causes of heart diseases. The company is focused on developing therapies that can potentially reduce the risk of heart attacks and other related diseases by targeting the genetic drivers of these conditions.
The co-founders of Verve Therapeutics Inc are Sekar Kathiresan, MD, and Andrew Bellinger, MD, PhD, both prominent researchers in the field of genetics and cardiovascular diseases. Dr. Kathiresan previously founded two successful genetic medicine companies - Editas Medicine and Verve Therapeutics, while Dr. Bellinger was the former Director of Translational Medicine at Merck.
Verve Therapeutics Inc.'s primary target is coronary artery disease, which is the leading cause of death worldwide. Other diseases that often go hand-in-hand with coronary artery disease, such as high cholesterol, are also in the company's sights. Through groundbreaking research and development, Verve Therapeutics is hoping to address a significant gap in the market for cardiovascular disease treatments.
The company's mission is to eliminate the genetic risk of cardiovascular disease through in vivo gene editing with unparalleled expertise in cardiovascular disease genetics, delivery systems, and protein engineering. Verve Therapeutics develops a pipeline of products to protect and prevent heart disease through cutting-edge technology and the CRISPR gene editing system.
Overall, Verve Therapeutics Inc. is a promising biotech company with an ambitious goal of revolutionizing gene-editing therapies for cardiovascular diseases. The company's highly experienced and dedicated team is comprised of renowned researchers and scientists committed to bringing innovative treatments that can change the lives of people at risk of coronary artery disease.
Company Address: 201 Brookline Avenue, Suite 601 Boston 2215 MA
Company Phone Number: 603-0070 Stock Exchange / Ticker: NASDAQ VERV
VERV is expected to report next financial results on March 01, 2024. |
|
|